Use of solid supported nucleophiles and electrophiles for the purification of non-peptide small molecule libraries
摘要:
Solid supported nucleophiles and electrophiles are employed to expedite the work-up and purification of a variety of amine alkylations and acylations. These solid suported scavengers are particularly advantageous for the construction of non-peptide libraries in a parallel array format. Copyright (C) 1996 Elsevier Science Ltd
Conversion of furfural to tetrahydrofuran-derived secondary amines under mild conditions
作者:Shi Jiang、Eric Muller、François Jerôme、Marc Pera-Titus、Karine De Oliveira Vigier
DOI:10.1039/d0gc00119h
日期:——
production of amino-containing compounds from biomass is an important goal of research programs. Starting from carbohydrate-based furfural, a simple and highly efficient system was developed for producing a library of secondary and tertiary tetrahydrofurfurylamines undermildconditions (25 °C/1 bar H2) with excellent yields (>90%). Commercially available Pd/Al2O3 proved to be a suitable catalyst and exhibited
由生物质生产含氨基化合物是研究计划的重要目标。从基于碳水化合物的糠醛开始,开发了一种简单高效的系统,可在温和条件下(25°C / 1 bar H 2)以优异的收率(> 90%)生产仲和叔四氢糠胺库。市场上可买到的Pd / Al 2 O 3被证明是合适的催化剂,并表现出出色的性能。
Lewis Acid Catalyzed Cyclization Reactions of Ethenetricarboxylates via Intramolecular Hydride Transfer
examined. The reaction of the amides bearing cyclic ether and acetal groups in the presence of Lewis acid such as Sc(OTf)3 gave spirocyclic piperidine derivatives as major products. The cyclized products may be formed via intramolecular hydride transfer. The reaction mechanism was examined by the DFT calculations. The scope and limitations of the hydride transfer/cyclization reactions of amides of
[EN] SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF<br/>[FR] LIGANDS DU RÉCEPTEUR SIGMA-1 ET SES UTILISATIONS THÉRAPEUTIQUES
申请人:UNIV STRASBOURG
公开号:WO2021123174A1
公开(公告)日:2021-06-24
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.
HCOONa can completely shift N-alkylation to the 5a side by significantly reducing activation energy from 55.3 to 46.8 kJ mol−1 in the 4a-to-5a transfer-hydrogenation stage, which leads to a 15-fold increase in the rate constant for 4a hydrogenation at 140 °C. This research study highlights a kinetic understanding of N-alkylation for the construction of biomass-based amines.